BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie will present poster abstracts from its ADDRESS-LC Phase 2 trial in Long COVID and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson's disease at the American Neurological Association's ANA2026 meeting in San Diego, October 17-20, 2026. SUNRISE-PD enrolled 57 treatment-naive early Parkinson's patients and showed improvements in inflammatory biomarkers and multiple clinical measures versus placebo; ADDRESS-LC enrolled roughly 200 patients but did not achieve statistical significance in the intent-to-treat population.
Key figures
- Drug Name
- bezisterim (NE3107)
- Phase Of Trial
- Phase 2
- Address lc enrollment
- approximately 200 (203 referenced in forward-looking statements)
- Sunrise pd enrollment
- 57
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.